Business Wire

ZAYO-GROUP

16.1.2023 14:01:42 CET | Business Wire | Press release

Share
Zayo Boosts Infrastructure Leadership in Europe with Pivotal Fiber Expansion Connecting Global Internet Hubs of Paris and Marseille

Zayo Group Holdings, Inc., a leading global communications infrastructure platform, announced the deployment of a new 400G enabled route connecting Paris and Marseille—including first-in-market network hardening of this critical route leveraging next-generation fiber technologies—to provide enterprises with an easier and more secure way to transport rapidly increasing high-bandwidth traffic from these top-ten global internet hubs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005067/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Map of Zayo's new 400G enabled route connecting Paris and Marseille (Graphic: Business Wire)

“We are continuously expanding, improving and diversifying our network in order to support our customers with their increasing bandwidth,” said Yannick Leboyer, Europe Chief Operating Officer at Zayo. “With several new subsea cable projects set to deploy in the coming years, Marseille is on its way to becoming one of the top five internet connectivity hubs globally, and Zayo is uniquely positioned to provide the necessary infrastructure to support this growth. The Paris-to-Marseille route is built to support and transport the fast-paced bandwidth growth and increasingly high demand for connectivity in these markets, giving customers a more reliable, scalable and secure way to share data to the rest of Europe and the U.S.”

Paris is the fourth largest internet connectivity hub in the world, and Marseille, a crossroad of several major exchanges between terrestrial and submarine networks, is projected to move from the seventh to the fifth largest global internet hub in the next three years. With six new subsea cables in Marseille scheduled for completion, including key gateways to Asia, Africa and the Middle East, capacity demands in Marseille are expected to quadruple by 2026. This is creating a rapidly increasing need for enterprises to transport traffic growth from these hubs throughout Europe and to other key commerce centers across the globe.

The new Paris-to-Marseille route from Zayo provides 24 terabytes of total expected capacity per fiber pair, critical triversity options, and 400G enablement for enterprises to manage this capacity growth and ensure secure, resilient connectivity to the rest of Europe and the United States. Beyond capacity, Zayo is hardening its network with new fiber technologies, making Zayo the first carrier with this next-generation fiber on the route connecting Paris to Marseille.

The route will also provide direct access to Bordeaux—the landing city for Amitié, a new private transatlantic cable that will connect the U.S. with the UK and France. Once ready for service, the connection will enable direct access to Asia, Africa, and the Middle East.

This latest investment from Zayo is part of the company’s overall strategy to overlay its European backbone and deliver high-capacity bandwidth across Europe, following the completion of its Zeus subsea cable in 2022, which provides the strongest connection between the UK and continental Europe. To date, Zayo owns and operates 2.2 million kilometers of fiber and connects 16 key metro markets and nine countries across Europe.

To learn more about Zayo’s global network, please visit https://www.zayo.com/network/.

About Zayo Group Holdings, Inc.

Zayo Group Holdings, Inc. is the leading global communications infrastructure platform, delivering a range of solutions, including fiber & transport, packet and managed edge services. Zayo owns and operates a Tier 1 IP backbone spanning 137,000 miles across North America and Europe. By providing this mission-critical bandwidth to its category-leading customers across the wireless, hyperscale, media, tech and finance industries, Zayo is fueling the innovations that are transforming society. For more information, visit https://zayo.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005067/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye